{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:02:03Z","timestamp":1787792523982,"version":"build-2784847793"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychoneuroendocrinology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.psyneuen.2015.04.011","type":"journal-article","created":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T18:19:15Z","timestamp":1429985955000},"page":"130-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose\u2013response study"],"prefix":"10.1016","volume":"58","author":[{"given":"Jing-Xu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Ai","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Tao","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-He","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair C.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-De","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psyneuen.2015.04.011_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.psym.2013.08.008","article-title":"Psychotropic-induced hyperprolactinemia: a clinical review","volume":"55","author":"Ajmal","year":"2014","journal-title":"Psychosomatics"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"Association AP","year":"1994"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0015","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0020","first-page":"290","article-title":"Aripiprazole reverses paliperidone-induced hyperprolactinemia","volume":"40","author":"Basterreche","year":"2012","journal-title":"Actas Esp. Psiquiatr."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0025","first-page":"CD006622","article-title":"Aripiprazole versus placebo for schizophrenia","author":"Belgamwar","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0030","series-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","first-page":"218","article-title":"The clinical global impressions scale","author":"Branch NPR","year":"1976"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0269881107088435","article-title":"A review of the association between antipsychotic use and hyperprolactinaemia","volume":"22","author":"Bushe","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0040","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","article-title":"Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study","volume":"107","author":"Byerly","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0045","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","article-title":"Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics","volume":"34","author":"Chen","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0050","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4088\/JCP.08l04671","article-title":"Aripiprazole treatment of risperidone-induced hyperprolactinemia","volume":"70","author":"Chen","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.schres.2011.02.016","article-title":"Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior","volume":"131","author":"Correll","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0060","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0065","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145710000490","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial","volume":"13","author":"Fleischhacker","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0070","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","article-title":"Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons","volume":"21","author":"Fraguas","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970 to 2009","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0080","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14740338.2012.683523","article-title":"Safety and tolerability of antipsychotic polypharmacy","volume":"11","author":"Gallego","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0085","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","article-title":"Mechanism of new antipsychotic medications: occupancy is not just antagonism","volume":"60","author":"Grunder","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0090","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0095","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0100","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/00048674.2011.589044","article-title":"Antipsychotic-induced hyperprolactinaemia","volume":"45","author":"Inder","year":"2011","journal-title":"Aust. N.Z. J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-3565(25)12799-7","article-title":"Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland","volume":"277","author":"Inoue","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/YIC.0b013e328351c8c4","article-title":"Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study","volume":"27","author":"Jeong","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0115","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/0269881109348157","article-title":"Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials","volume":"24","author":"Kane","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","article-title":"Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine","volume":"68","author":"Kane","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0125","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","article-title":"A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0130","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0135","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1038\/npp.2008.33","article-title":"Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F] fallypride","volume":"33","author":"Kegeles","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0140","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1471-244X-13-214","article-title":"Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic Elevated prolactin)","volume":"13","author":"Kelly","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0145","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1176\/appi.ajp.2007.07071043","article-title":"Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?","volume":"164","author":"Kessler","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0150","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/jcbfm.2011.180","article-title":"Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship","volume":"32","author":"Kim","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/YCO.0b013e328355e1ac","article-title":"Osteoporosis and fracture risk in people with schizophrenia","volume":"25","author":"Kishimoto","year":"2012","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0160","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00737-010-0150-x","article-title":"Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature","volume":"13","author":"Kuloglu","year":"2010","journal-title":"Arch. Womens Ment. Health"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0165","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-0033-1347177","article-title":"Sexual dysfunction related to psychotropic drugs: a critical review, Part II: Antipsychotics","volume":"46","author":"La Torre","year":"2013","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0170","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0180","doi-asserted-by":"crossref","first-page":"e70179","DOI":"10.1371\/journal.pone.0070179","article-title":"Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials","volume":"8","author":"Li","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0185","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hup.1116","article-title":"Hyperprolactinemia associated with psychotropics\u2014a review","volume":"25","author":"Madhusoodanan","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0265","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","article-title":"Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment","volume":"65","author":"Montgomery","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0190","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4088\/JCP.12028ah1","article-title":"Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice","volume":"74","author":"Newcomer","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0195","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0200","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2710.2008.01009.x","article-title":"Attenuation of risperidone-induced hyperprolactinemia with the addition of aripiprazole","volume":"34","author":"Rainka","year":"2009","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0205","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.pnpbp.2010.06.003","article-title":"Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia","volume":"34","author":"Rocha","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0210","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1440-1819.2008.01859.x","article-title":"Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia","volume":"62","author":"Saitis","year":"2008","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0215","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0225","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.4088\/JCP.09r05060gre","article-title":"A systematic review of aripiprazole\u2014dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring","volume":"71","author":"Sparshatt","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0230","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2012.12.027","article-title":"Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics","volume":"145","author":"Suzuki","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0235","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/JCP.0b013e318205e1aa","article-title":"Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long acting injection","volume":"31","author":"van Kooten","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0240","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.pnpbp.2012.10.010","article-title":"Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs","volume":"40","author":"Wang","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0245","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia","volume":"30","author":"Yasui-Furukori","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0250","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","article-title":"Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride","volume":"27","author":"Yokoi","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0255","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.4088\/JCP.12m08189","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder","volume":"74","author":"Yoo","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2015.04.011_bib0260","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/JCP.0b013e3182970431","article-title":"Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection","volume":"33","author":"Ziadi Trives","year":"2013","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Psychoneuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453015001511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453015001511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T16:48:26Z","timestamp":1759682906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306453015001511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":53,"alternative-id":["S0306453015001511"],"URL":"https:\/\/doi.org\/10.1016\/j.psyneuen.2015.04.011","relation":{},"ISSN":["0306-4530"],"issn-type":[{"value":"0306-4530","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose\u2013response study","name":"articletitle","label":"Article Title"},{"value":"Psychoneuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psyneuen.2015.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}